Marktanalyse - Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2016

Global Markets Direct
12.2016
58 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperphosphatemia In Chronic Kidney Disease — Pipeline Review, H2 2016, provides an overview of the Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline landscape.

Hyperphosphatemia, that is, abnormally high serum phosphate levels, can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. This condition is most commonly seen in patients with chronic kidney disease. Signs and symptoms include fatigue, nausea, sleep disturbances, shortness of breath, bone and joint pain, pruritus and rash. Treatment includes phosphate binders and diuretics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperphosphatemia In Chronic Kidney Disease — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperphosphatemia In Chronic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 3, 2, 1, 1 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders).
- The pipeline guide reviews pipeline therapeutics for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Hyperphosphatemia In Chronic Kidney Disease Overview 7

Therapeutics Development 8

Pipeline Products for Hyperphosphatemia In Chronic Kidney Disease - Overview 8

Pipeline Products for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis 9

Hyperphosphatemia In Chronic Kidney Disease - Therapeutics under Development by Companies 10

Hyperphosphatemia In Chronic Kidney Disease - Therapeutics under Investigation by Universities/Institutes 11

Hyperphosphatemia In Chronic Kidney Disease - Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Hyperphosphatemia In Chronic Kidney Disease - Products under Development by Companies 15

Hyperphosphatemia In Chronic Kidney Disease - Products under Investigation by Universities/Institutes 16

Hyperphosphatemia In Chronic Kidney Disease - Companies Involved in Therapeutics Development 17

3SBio Inc 17

Ardelyx Inc 18

Daiichi Sankyo Company Ltd 19

Medice Arzneimittel Putter GmbH & Co KG 20

OPKO Health Inc 21

PDX Pharmaceuticals LLC 22

Shield Therapeutics Plc 23

Spectrum Pharmaceuticals Inc 24

Toray Industries Inc 25

Hyperphosphatemia In Chronic Kidney Disease - Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Target 27

Assessment by Mechanism of Action 29

Assessment by Route of Administration 31

Assessment by Molecule Type 32

Drug Profiles 34

DS-2330 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

fermagate - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

JPH-101 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

niacinamide - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

PDX-004 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

PT-20 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

RDX-002 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

sevelamer carbonate - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia In CKD - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Small Molecules to Target Phosphate for Hyperphosphatemia In Chronic Kidney Disease - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

SPI-014 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

tenapanor hydrochloride - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

TRK-390 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

VS-501 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects 51

Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products 52

Hyperphosphatemia In Chronic Kidney Disease - Product Development Milestones 53

Featured News & Press Releases 53

May 07, 2015: Phosphate Therapeutics announces positive results in the PEACH pivotal study of its novel phosphate binder (PT20) for the treatment of hyperphosphataemia 53

Feb 02, 2015: Ardelyx Reports Results from Phase 2b Clinical Trial Evaluating Tenapanor in Treating Hyperphosphatemia in Chronic Kidney Disease Patients on Hemodialysis 54

Jan 07, 2013: Spectrum Pharma Announces Positive RenaZorb Phase I Clinical Data Demonstrating Robust Activity In Easy-to-swallow Pill Formulation 54

May 29, 2012: Spectrum Pharma Announces Enrollment Of First Group Of Patients In Phase I Clinical Trial Of RenaZorb 55

Dec 05, 2011: Spectrum Pharmaceuticals Files Investigational New Drug Application With FDA For SPI-014 56

Appendix 57

Methodology 57

Coverage 57

Secondary Research 57

Primary Research 57

Expert Panel Validation 57

Contact Us 57

Disclaimer 58





List of Tables

Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, H2 2016 8

Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Development, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Hyperphosphatemia In Chronic Kidney Disease - Pipeline by 3SBio Inc, H2 2016 17

Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Ardelyx Inc, H2 2016 18

Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 19

Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Medice Arzneimittel Putter GmbH & Co KG, H2 2016 20

Hyperphosphatemia In Chronic Kidney Disease - Pipeline by OPKO Health Inc, H2 2016 21

Hyperphosphatemia In Chronic Kidney Disease - Pipeline by PDX Pharmaceuticals LLC, H2 2016 22

Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Shield Therapeutics Plc, H2 2016 23

Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Spectrum Pharmaceuticals Inc, H2 2016 24

Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Toray Industries Inc, H2 2016 25

Assessment by Monotherapy Products, H2 2016 26

Number of Products by Stage and Target, H2 2016 28

Number of Products by Stage and Mechanism of Action, H2 2016 30

Number of Products by Stage and Route of Administration, H2 2016 31

Number of Products by Stage and Molecule Type, H2 2016 33

Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects, H2 2016 51

Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products, H2 2016 52





List of Figures

Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, H2 2016 8

Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy Products, H2 2016 26

Number of Products by Top 10 Targets, H2 2016 27

Number of Products by Stage and Top 10 Targets, H2 2016 27

Number of Products by Mechanism of Actions, H2 2016 29

Number of Products by Stage and Mechanism of Actions, H2 2016 29

Number of Products by Stage and Routes of Administration, H2 2016 31

Number of Products by Molecule Types, H2 2016 32

Number of Products by Stage and Molecule Types, H2 2016 32

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus